Numab | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

40 results for “Numab”

Trials

View all 10 →

Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1

15 participants · First posted Feb 22, 2016

Active, not recruiting

A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors

51 participants · First posted Jul 1, 2020

Active, not recruiting

A First-in-Human Study of PRL3-ZUMAB

38 participants · First posted Jun 19, 2017

Drugs

View all 18 →

NM49

ND-003

Organizations

Numab Therapeutics AG

Switzerland

Nulab, Inc.

United States

News

View all 10 →

Physiomics Secures New Contract with Numab Therapeutics for Inflammation Study

J&J Acquires Atopic Dermatitis Drug NM26 in $1.25 Billion Deal with Numab Therapeutics

Johnson & Johnson to Acquire Yellow Jersey Therapeutics for $1.25 Billion, Bolstering Atopic Dermatitis Pipeline

Page 1 of 4